Reneo Pharmaceuticals Stock Quote RPHM - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.74

Bid

1.70

Ask

1.83

Volume

82,987

1.70 Day's Range 1.76

0.9801 52 Week Range 11.295

Market Cap

56.963M

Previous Close

1.76

Open

1.72

Last Trade

629

1.74

(priorref)

Last Trade Time

Financial Volume

$ 141,989

VWAP

1.711

Average Volume (3m)

204,980

Shares Outstanding

33,311,787

Dividend Yield

PE Ratio

-0.74

Earnings Per Share (EPS)

-2.32

Revenue

Net Profit

-77.39M

Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing ... Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

reneopharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Reneo Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RPHM. The last closing price for Reneo Pharmaceuticals was $1.76. Over the last year, Reneo Pharmaceuticals shares have traded in a share price range of $ 0.9801 to $ 11.295.

Reneo Pharmaceuticals currently has 33,311,787 shares outstanding. The market capitalization of Reneo Pharmaceuticals is $56.96 million. Reneo Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.74.

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.03	1.75438596491	1.71	1.92	1.63	140536	1.72906757	CS
4	0.06	3.57142857143	1.68	1.92	1.63	92861	1.70644653	CS
12	0.1	6.09756097561	1.64	1.92	1.55	204980	1.65343931	CS
26	-6.5	-78.8834951456	8.24	8.74	0.9801	630307	2.11602086	CS
52	-6.57	-79.0613718412	8.31	11.295	0.9801	394986	3.22106553	CS
156	-11.26	-86.6153846154	13	14.95	0.9801	169938	3.85869103	CS
260	-13.56	-88.6274509804	15.3	16.83	0.9801	170752	3.97821202	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TWGTop Wealth Group Holding Ltd	$ 3.73 (101.62%)	36.52M
CSLRComplete Solaria Inc	$ 0.465319 (75.59%)	16.64M
SHOTWSafety Shot Inc	$ 0.48 (60.00%)	6.71k
EGOXNext e GO NV	$ 0.0515 (43.06%)	333.3M
MNDRMobile health Network Solutions	$ 27.2386 (33.72%)	10.35M
YYAIConnexa Sports Technologies Inc	$ 0.8943 (-57.21%)	13.4M
SBFMSunshine Biopharma Inc	$ 1.77 (-46.69%)	11.9M
GTIGraphjet Technology	$ 6.43 (-33.09%)	95.33k
ISPCiSpecimen Inc	$ 0.2883 (-31.52%)	2.86M
BGLCBioNexus Gene Lab Corporation	$ 0.5998 (-29.32%)	735.88k
EGOXNext e GO NV	$ 0.0515 (43.06%)	333.3M
SQQQProShares UltraPro Short QQQ	$ 12.84 (6.38%)	219.91M
AGBAAGBA Group Holding Ltd	$ 1.255 (21.84%)	128.79M
TQQQProShares UltraPro QQQ	$ 49.48 (-6.20%)	125.4M
SINTSiNtx Technologies Inc	$ 0.0414 (3.50%)	109.94M